Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Cavo

Showing results (31-40 of 506) with videos related to

Pageof 51
Sort By:
Leukemia & Lymphoma|June 3, 2014
Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial dataAntonio Palumbo, Massimo Offidani, Francesca Patriarca, et al.
International Journal of Molecular Sciences|September 19, 2020
A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and FludarabineDarina Ocadlikova, Clara Iannarone, Anna Rita Redavid, et al.
Hematological Oncology|July 24, 2019
Spontaneous remission of follicular lymphomaAlice Morigi, Beatrice Casadei, Lisa Argnani, et al.
European Journal of Haematology|August 13, 2017
Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III studyEvangelos Terpos, Marco Gobbi, Anna Potamianou, et al.
Leukemia Research|April 17, 2026
An Italian Delphi consensus on the current and future burden and clinical management of lenalidomide-refractory multiple myelomaPaolo Corradini, Pellegrino Musto, Carlotta Galeone, et al.
Cancer Genetics|January 3, 2022
t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalitiesCarmen Baldazzi, Simona Luatti, Giulia Marzocchi, et al.
Expert Opinion on Biological Therapy|December 9, 2024
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myelomaKatia Mancuso, Simona Barbato, Marco Talarico, et al.
Expert Review of Hematology|October 3, 2013
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitorsGabriele Gugliotta, Fausto Castagnetti, Miriam Fogli, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|January 3, 2015
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myelomaEnrica Borsi, Carolina Terragna, Annamaria Brioli, et al.
Translation (Austin, Tex.)|January 30, 2016
Cap dependent translation contributes to resistance of myeloma cells to bortezomibMarilena Mancino, Stefano Grosso, Carolina Terragna, et al.
Pageof 51

Showing results (31-40 of 506) with videos related to

Sort By:
Pageof 51
Leukemia & Lymphoma|June 3, 2014
Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial dataAntonio Palumbo, Massimo Offidani, Francesca Patriarca, et al.
International Journal of Molecular Sciences|September 19, 2020
A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and FludarabineDarina Ocadlikova, Clara Iannarone, Anna Rita Redavid, et al.
Hematological Oncology|July 24, 2019
Spontaneous remission of follicular lymphomaAlice Morigi, Beatrice Casadei, Lisa Argnani, et al.
European Journal of Haematology|August 13, 2017
Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III studyEvangelos Terpos, Marco Gobbi, Anna Potamianou, et al.
Leukemia Research|April 17, 2026
An Italian Delphi consensus on the current and future burden and clinical management of lenalidomide-refractory multiple myelomaPaolo Corradini, Pellegrino Musto, Carlotta Galeone, et al.
Cancer Genetics|January 3, 2022
t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalitiesCarmen Baldazzi, Simona Luatti, Giulia Marzocchi, et al.
Expert Opinion on Biological Therapy|December 9, 2024
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myelomaKatia Mancuso, Simona Barbato, Marco Talarico, et al.
Expert Review of Hematology|October 3, 2013
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitorsGabriele Gugliotta, Fausto Castagnetti, Miriam Fogli, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|January 3, 2015
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myelomaEnrica Borsi, Carolina Terragna, Annamaria Brioli, et al.
Translation (Austin, Tex.)|January 30, 2016
Cap dependent translation contributes to resistance of myeloma cells to bortezomibMarilena Mancino, Stefano Grosso, Carolina Terragna, et al.
Pageof 51